| Background:Chronic heart failure(CHF)has a high incidence and is the ultimate development direction of various cardiovascular diseases.Among its numerous causes,coronary atherosclerotic heart disease(referred to as:coronary heart disease)is the most common.Modern medical treatment of coronary heart disease and chronic heart failure has made patients achieve better clinical efficacy and prolonged survival,but the quality of life of patients still needs to be strengthened.Chinese medicine has certain advantages in the prevention and treatment of coronary heart disease and chronic heart failure,especially in enhancing the quality of life of patients.Based on the good clinical efficacy and previous research results of Yiqi Huoxue Lishui prescription over the years,this study aims to explore the effect of Yiqi Huoxue Lishui prescription on the cardiac function and quality of life of CHF patients with coronary heart disease,while observing the impact of activity tolerance,traditional Chinese medicine(TCM)syndrome,main symptoms and NT-proBNP,with a view to providing evidence-based medical evidence for the clinical application of Yiqi Huoxue Lishui prescription.Objective:To explore the effect of Yiqi Huoxue Lishui prescription on cardiac function and quality of life in CHF patients with coronary heart disease.Methods:In our study,CHF patients with coronary heart disease were used as the research subjects,and the random method was the random number table method.Both groups were treated with conventional Western medicine,and the treatment group and the control group were supplemented with Yiqi Huoxue Lishui prescription and trimetazidine hydrochloride respectively.The course of treatment was 4 weeks.The primary outcome measures are cardiac function and quality of life,secondary outcome measures are 6-minute walk test(6MWT),TCM syndrome score,major symptom score and NT-proBNP.Results:62 patients diagnosed with CHF due to coronary heart disease were enrolled and randomized at Dongfang Hospital of Beijing University of Chinese Medicine.Finally,59 patients completed the study with 3 patients lost to follow-up,of which 29 patients(2 patients lost to follow-up)were in the treatment group and 30 patients(1 patient lost to follow-up)in the control group.Baseline conditions were well balanced between the two groups.(1)Primary outcome measures:? cardiac function:the total effective rate of cardiac function(NYHA classification)in the treatment group and the control group was 75.9%and 50.0%respectively,and the improvement in the treatment group was significantly better than that in the control group(P<0.05).The left ventricular ejection fraction(LVEF)of both groups was higher than before treatment(P<0.05),but there was no statistical difference between the two groups after treatment(P>0.05).?Quality of life:after treatment,the total score of quality of life and scores of various fields in the two groups were improved(P<0.05).After treatment,the improvement of the total score,physiological function,role restriction and vitality in the treatment group was better than that in the control group(P<0.05),but in terms of social function,mental health,and medical support,there was no statistical difference between the two groups after treatment(P>0.05).(2)Secondary outcome measures:?6MWT:after treatment,the 6MWT distance in both groups was longer than that before treatment(P<0.05),and the treatment group was better than the control group(P<0.05).?TCM syndrome and primary symptom score:after treatment,the total effective rate of TCM syndrome in the treatment group and the control group was 82.8%and 56.7%respectively,and the improvement in the treatment group was significantly better than that in the control group(P<0.05).After treatment,the main symptom scores of the two groups of patients decreased compared with that before treatment(P<0.05).Among them,the scores of shortness of breath,fatigue,and asthma symptoms were more significantly reduced in the treatment group(P<0.05).? NT-proBNP:after treatment,the level of NT-proBNP in the two groups was lower than that before treatment(P<0.05),and it was more significant in the treatment group(P<0.05).Conclusion:Yiqi Huoxue Lishui prescription has advantages in improving cardiac function,quality of life,activity tolerance and clinical symptoms and reducing NT-proBNP levels of CHF patients with coronary heart disease. |
PDF Full Text Request